FDA Issues Early Communication about Ongoing Safety Review of Weight Loss Drug Orlistat

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA Issues Early Communication about Ongoing Safety Review of Weight Loss Drug Orlistat

FDA Issues Early Communication about Ongoing Safety Review of Weight Loss Drug Orlistat
Mon, 24 Aug 2009 16:23:00 -0500

The U.S. Food and Drug Administration announced today that it is reviewing adverse event reports of liver injury in patients taking the weight loss drug orlistat, marketed as the prescription drug Xenical and the over-the-counter medication Alli.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420